全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Topical Pimecrolimus as a New Optional Treatment in Cutaneous Sarcoidosis of Lichenoid Type

DOI: 10.1155/2014/976851

Full-Text   Cite this paper   Add to My Lib

Abstract:

We report the case of cutaneous sarcoidosis of lichenoid type successfully treated with pimecrolimus. For the first time in the literature, we propose the use of this topical calcineurin inhibitor for the treatment of the cases refractory to common therapy regimens. 1. Introduction Lichenoid sarcoidosis is an extremely rare cutaneous manifestation of sarcoidosis, occurring in 1%-2% of all cases and presenting with multiple erythematous or violaceous, slightly scaling maculopapules localized on the trunk, limbs, and face, without systemic involvement. Different therapeutic approaches have been described for the treatment of cutaneous sarcoidosis, but the lesions are often refractory to the common treatments. We described the case of a female patient affected by cutaneous sarcoidosis of lichenoid type successfully treated with topical calcineurin inhibitor Pimecrolimus, never been reported in the literature until now. 2. A Case Report A 66-year-old woman was referred to our department with a 6-month history of 1-2?mm diameter, violaceous, nonfollicular, infiltrated lichenoid papules with a tendency to group, located on the right knee (Figure 1(a)). The onset had been abrupt and no antecedent of trauma was found. She had been using a clobetasol ointment once daily for 2 months with no improvement of the lesions. Figure 1: (a) Infiltrated, nonfollicular, lichenoid papules with a tendency to group, located on both knees; (b) a nearly complete remission of the lesions after 6-months therapy with topical 1% pimecrolimus. She did not complain of any systemic symptoms or take any kind of drugs. In the past medical history, no relevant diseases were referred, except for a papillary thyroid carcinoma excised 4 years before. General physical examination did not reveal any abnormality or lymphadenopathy. Cutaneous biopsy of one of the lesions revealed mild thinning of the epidermis, and a nonnecrotizing lymphohstiociytic granulomatous infiltrate in the superficial and deep dermis (Figures 2 and 3). Neither eosinophils nor mucin were seen. Gram stain, stain for fungi, and special stains for mycobacteria were negative. We also performed a videodermoscopy evaluation of the lesions, showing a round to oval yellow-brown lesion with absence of white Wickham striae (Figure 4). Figure 2: H&E staining, 100x magnification. Epidermis presents rete ridges flattening and orthotopic hyperkeratosis. In the deep dermal layer a sarcoidosis-like granulomatous reaction is visible. Figure 3: H&E staining, 200x magnification. Sarcoidosis-like granulomas are composed by epithelioid

References

[1]  K. Fujii, H. Okamoto, M. Onuki, and T. Horio, “Recurrent follicular and lichenoid papules of sarcoidosis,” European Journal of Dermatology, vol. 10, no. 4, pp. 303–305, 2000.
[2]  F. Vazquez-Lopez, L. Palacios-Garcia, S. Gomez-Diez, and G. Argenziano, “Dermoscopy for discriminating between lichenoid sarcoidosis and lichen planus,” Archives of Dermatology, vol. 147, no. 9, p. 1130, 2011.
[3]  H. Tsuboi, K. Yonemoto, and K. Katsuoka, “A 14-year-old girl with lichenoid sarcoidosis successfully treated with tacrolimus,” Journal of Dermatology, vol. 33, no. 5, pp. 344–348, 2006.
[4]  S. K. Seo, J. S. Yeum, J. C. Suh, and G. Y. Na, “Lichenoid sarcoidosis in a 3-year-old girl,” Pediatric Dermatology, vol. 18, no. 5, pp. 384–387, 2001.
[5]  C. Badgwell and T. Rosen, “Cutaneous sarcoidosis therapy updated,” Journal of the American Academy of Dermatology, vol. 56, no. 1, pp. 69–83, 2007.
[6]  R. J. Young III, R. T. Gilson, D. Yanase, and D. M. Elston, “Cutaneous sarcoidosis,” International Journal of Dermatology, vol. 40, no. 4, pp. 249–253, 2001.
[7]  S. Sawada, G. Suzuki, Y. Kawase, and F. Takaku, “Novel immunosuppressive agent, FK506: in vitro effects of the cloned T cell activation,” Journal of Immunology, vol. 139, no. 6, pp. 1797–1803, 1987.
[8]  E. J. M. Van Leent, M. Gr?ber, M. Thurston, A. Wagenaar, P. I. Spuls, and J. D. Bos, “Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis,” Archives of Dermatology, vol. 134, no. 7, pp. 805–809, 1998.
[9]  S. Vano-Galvan, M. Fernandez-Guarino, L. P. Carmona, A. Harto, R. Carrillo, and P. Jaén, “Lichenoid type of cutaneous sarcoidosis: great response to topical tacrolimus,” European Journal of Dermatology, vol. 18, no. 1, pp. 89–90, 2008.
[10]  V. de Francesco, A. S. Cathryn, and F. Piccirillo, “Successful topical treatment of cutaneous sarcoidosis with macrolide immunomodulators,” European Journal of Dermatology, vol. 17, no. 5, pp. 454–455, 2007.
[11]  R. Gutzmer, B. V?lker, A. Kapp, and T. Werfel, “Successful topical treatment of cutaneous sarcoidosis with tacrolimus ointment,” Hautarzt, vol. 54, no. 12, pp. 1193–1197, 2003.
[12]  C. M. Green, “Topical tacrolimus for the treatment of cutaneous sarcoidosis,” Clinical and Experimental Dermatology, vol. 32, no. 4, pp. 457–458, 2007.
[13]  N. Katoh, H. Mihara, and H. Yasuno, “Cutaneous sarcoidosis successfully treated with topical tacrolimus,” British Journal of Dermatology, vol. 147, no. 1, pp. 154–156, 2002.
[14]  T. Zuberbier, S. U. Chong, K. Grunow et al., “The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils,” Journal of Allergy and Clinical Immunology, vol. 108, no. 2, pp. 275–280, 2001.
[15]  H. P. Gschwind, F. Waldmeier, M. Zollinger, A. Schweitzer, and M. Grassberger, “Pimecrolimus: skin disposition after topical administration in minipigs in vivo and in human skin in vitro,” European Journal of Pharmaceutical Sciences, vol. 33, no. 1, pp. 9–19, 2008.
[16]  H. M. Weiss, M. Fresneau, T. Moenius, A. Stuetz, and A. Billich, “Binding of pimecrolimus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application,” Drug Metabolism and Disposition, vol. 36, no. 9, pp. 1812–1818, 2008.

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133

WeChat 1538708413